Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.

The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer progression, creating a significant variability within primary tumors as well...

Descripción completa

Detalles Bibliográficos
Autores: Godoy-Ortiz, Ana, Sanchez-Muñoz, Alfonso, Chica Parrado, Maria Rosario, Álvarez, Martina, Ribelles, Nuria, Rueda Dominguez, Antonio, Alba, Emilio
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/17925
Acceso en línea:http://hdl.handle.net/20.500.12105/17925
Access Level:acceso abierto
Palabra clave:HER2-enriched
HER2-positive
Breast cancer
Heterogeneity
Intrinsic subtype
Molecular
id ES_fd31ba972799e88fa8a54ceefc855988
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/17925
network_acronym_str ES
network_name_str España
repository_id_str
spelling Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.Godoy-Ortiz, AnaSanchez-Muñoz, AlfonsoChica Parrado, Maria RosarioÁlvarez, MartinaRibelles, NuriaRueda Dominguez, AntonioAlba, EmilioHER2-enrichedHER2-positiveBreast cancerHeterogeneityIntrinsic subtypeMolecularThe main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer progression, creating a significant variability within primary tumors as well as between the primary breast cancer and their metastases, a hypothesis have already demonstrated in retrospective studies (1). A clear example of this is the HER2-positive breast cancer. In these tumors, we can find all of the transcriptional subtypes of breast cancer, even the basal like or luminal A subtypes. Although the HER2-enriched is the most representative transcriptional subtype in the HER2-positive breast cancer, we can find it too in breast cancers with HER2-negative status. This intrinsic subtype shows a high expression of the HER2 and is associated with proliferation-related genes clusters, among other features. Therefore, two hypotheses can be suggested. First, the HER2 amplification can be a well-defined driver event present in all of the intrinsic subtypes, and not a subtype marker isolated. Secondly, HER2-enriched subtype can have a distinctive transcriptional landscape independent of HER2 amplification. In this review, we present an extensive revision about the last highlights and advances in clinical and genomic settings of the HER2-positive breast cancer and the HER2-enriched subtype, in an attempt to improving the knowledge of the underlying biology of both entities and to explaining the intrinsic heterogeneity of HER2-positive breast cancers.20242024-02-1020192019-10-2920192019-10-29research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttp://hdl.handle.net/20.500.12105/17925reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/179252026-06-12T12:43:37Z
dc.title.none.fl_str_mv Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
title Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
spellingShingle Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Godoy-Ortiz, Ana
HER2-enriched
HER2-positive
Breast cancer
Heterogeneity
Intrinsic subtype
Molecular
title_short Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
title_full Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
title_fullStr Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
title_full_unstemmed Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
title_sort Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
dc.creator.none.fl_str_mv Godoy-Ortiz, Ana
Sanchez-Muñoz, Alfonso
Chica Parrado, Maria Rosario
Álvarez, Martina
Ribelles, Nuria
Rueda Dominguez, Antonio
Alba, Emilio
author Godoy-Ortiz, Ana
author_facet Godoy-Ortiz, Ana
Sanchez-Muñoz, Alfonso
Chica Parrado, Maria Rosario
Álvarez, Martina
Ribelles, Nuria
Rueda Dominguez, Antonio
Alba, Emilio
author_role author
author2 Sanchez-Muñoz, Alfonso
Chica Parrado, Maria Rosario
Álvarez, Martina
Ribelles, Nuria
Rueda Dominguez, Antonio
Alba, Emilio
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv HER2-enriched
HER2-positive
Breast cancer
Heterogeneity
Intrinsic subtype
Molecular
topic HER2-enriched
HER2-positive
Breast cancer
Heterogeneity
Intrinsic subtype
Molecular
description The main obstacle for designing effective treatment approaches in breast cancer is the extensive and the characteristic heterogeneity of this tumor. The vast majority of critical genomic changes occurs during breast cancer progression, creating a significant variability within primary tumors as well as between the primary breast cancer and their metastases, a hypothesis have already demonstrated in retrospective studies (1). A clear example of this is the HER2-positive breast cancer. In these tumors, we can find all of the transcriptional subtypes of breast cancer, even the basal like or luminal A subtypes. Although the HER2-enriched is the most representative transcriptional subtype in the HER2-positive breast cancer, we can find it too in breast cancers with HER2-negative status. This intrinsic subtype shows a high expression of the HER2 and is associated with proliferation-related genes clusters, among other features. Therefore, two hypotheses can be suggested. First, the HER2 amplification can be a well-defined driver event present in all of the intrinsic subtypes, and not a subtype marker isolated. Secondly, HER2-enriched subtype can have a distinctive transcriptional landscape independent of HER2 amplification. In this review, we present an extensive revision about the last highlights and advances in clinical and genomic settings of the HER2-positive breast cancer and the HER2-enriched subtype, in an attempt to improving the knowledge of the underlying biology of both entities and to explaining the intrinsic heterogeneity of HER2-positive breast cancers.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-10-29
2019
2019-10-29
2024
2024-02-10
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/17925
url http://hdl.handle.net/20.500.12105/17925
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425517705297920
score 15,811543

Similares en LA Referencia